Literature DB >> 31892469

A Case Series of Preoperative Endovascular Stenting in Patients Undergoing Postchemotherapy Resection of Complex Oncologic Masses.

Gregory Amend1, Roland Palvolgyi1, Victor M Rodriguez2, Richard J Bold3, Christopher P Evans4.   

Abstract

The incidence of complications for postchemotherapy (PC) resections is high. Severe intraoperative hemorrhage during retroperitoneal lymph node dissection is of significant concern. The safety and efficacy of endovascular technology in vascular surgery have been demonstrated, but no studies have incorporated endovascular stenting in preoperative planning. We present a case series of four patients with nonseminomatous germ cell tumors who underwent preoperative endovascular stenting to identify and protect major vascular structures encased by complex PC tumors. We measured operative time, estimated blood loss, intraoperative transfusion requirement, length of stay, and postoperative complications. In all cases, surgery progressed without full continuous identification of the major vascular structures and their branches because of the assurance that hemorrhage would be controlled should they be breached. PATIENT
SUMMARY: Preoperative endovascular stenting may be an effective approach for minimizing intraoperative hemorrhage and operative time in patients undergoing bulky postchemotherapy dissection. Additional studies are needed to better clarify patient selection criteria and quantify the efficacy and adverse consequences.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endovascular stenting; Intraoperative complications; Postchemotherapy retroperitoneal lymph node dissection

Mesh:

Year:  2019        PMID: 31892469     DOI: 10.1016/j.euo.2019.11.004

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  1 in total

1.  Correlation between Selection of Time Window for Acute Cerebral Infarction and Efficacy of Intravascular Stent Implantation.

Authors:  Guanqing Feng; Yu Gong
Journal:  J Healthc Eng       Date:  2022-02-08       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.